CoChat
Sign Up
Cited by 105Chemotherapy-related skin toxicityHER2/EGFR in Cancer ResearchDrug-Induced Adverse Reactions

Genetic Ablation of Epidermal EGFR Reveals the Dynamic Origin of Adverse Effects of Anti-EGFR Therapy

Open access
Mascia, Francesca, Lam, Gary, Keith, Christopher, Garber, Caroline, Steinberg, Seth M., Kohn, Elise, Yuspa, Stuart H.·2013·Science Translational Medicine
DOI 10.1126/scitranslmed.3005773PMC PMC6324537
Open this paper in CoChat — free account

Abstract

Epidermal EGFR ablation causes a localized cutaneous rash and a systemic inflammatory syndrome.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3005773

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 38

  1. [1]Ciardiello F, Tortora G, EGFR antagonists in cancer treatment. The New England journal of medicine 358, 1160 (3 13, 2008). 18337605
  2. [2]Lacouture ME, Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature reviews. Cancer 6, 803 (10, 2006). 16990857
  3. [3]Peeters M, Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115, 1544 (4 1, 2009). 19189371
  4. [4]Perez-Soler R, Saltz L, Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Journal of clinical oncology: official journal of the American Society of Clinical Oncology 23, 5235 (8 1, 2005). 16051966
  5. [5]Wacker B, Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clinical cancer research: an official journal of the American Association for Cancer Research 13, 3913 (7 1, 2007). 17606725
  6. [6]Guttman-Yassky E, Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 46, 2010 (7, 2010). 20621734
  7. [7]Han SS, Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. The British journal of dermatology 162, 371 (2 1, 2010). 19903175
  8. [8]Hansen LA, Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. The American journal of pathology 150, 1959 (6, 1997). 9176390 PMC1858310
  9. [9]Murillas R, Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. The EMBO journal 14, 5216 (11 1, 1995). 7489711 PMC394631
  10. [10]Sibilia M, Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart. Development 130, 4515 (10, 2003). 12925580
  11. [11]Mascia F, Mariani V, Girolomoni G, Pastore S, Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. The American journal of pathology 163, 303 (7, 2003). 12819035 PMC1868171
  12. [12]Pastore S, ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol 174, 5047 (4 15, 2005). 15814736
  13. [13]Blaydon DC, Inflammatory skin and bowel disease linked to ADAM17 deletion. The New England journal of medicine 365, 1502 (10 20, 2011). 22010916
  14. [14]Argiris A, Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral oncology 47, 961 (10, 2011). 21889392 PMC3402506
  15. [15]Debucquoy A, Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27, 2751 (6 10, 2009). 19332731
  16. [16]Kanazawa S, Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib. Journal of cancer research and clinical oncology 132, 719 (11, 2006). 16835747 PMC12161027
  17. [17]Kimura H, Kasahara K, Sekijima M, Tamura T, Nishio K, Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. Lung Cancer 50, 393 (12, 2005). 16153743
  18. [18]Posadas EM, A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109, 1323 (4 1, 2007). 17330838 PMC2778218
  19. [19]Ramirez A, A keratin K5Cre transgenic line appropriate for tissue-specific or generalized Cre-mediated recombination. Genesis 39, 52 (5, 2004). 15124227
  20. [20]Lee TC, Threadgill DW, Generation and validation of mice carrying a conditional allele of the epidermal growth factor receptor. Genesis 47, 85 (2, 2009). 19115345 PMC9060398
  21. [21]Segre JA, Epidermal barrier formation and recovery in skin disorders. The Journal of clinical investigation 116, 1150 (5, 2006). 16670755 PMC1451215
  22. [22]Threadgill DW, Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269, 230 (7 14, 1995). 7618084
  23. [23]Cataisson C, Pearson AJ, Torgerson S, Nedospasov SA, Yuspa SH, Protein kinase C alpha-mediated chemotaxis of neutrophils requires NF-kappa B activity but is independent of TNF alpha signaling in mouse skin in vivo. J Immunol 174, 1686 (2 1, 2005). 15661932
  24. [24]Adachi O, Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9, 143 (7, 1998). 9697844
  25. [25]Laubach VE, Shesely EG, Smithies O, Sherman PA, Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proceedings of the National Academy of Sciences of the United States of America 92, 10688 (11 7, 1995). 7479866 PMC40677
  26. [26]Kuziel WA, Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proceedings of the National Academy of Sciences of the United States of America 94, 12053 (10 28, 1997). 9342361 PMC23699
  27. [27]Zaynagetdinov R, A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J Immunol 187, 5703 (12 1, 2011). 22048774 PMC3221921
  28. [28]Van Rooijen N, Sanders A, Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. Journal of immunological methods 174, 83 (9 14, 1994). 8083541
  29. [29]Mascia F, Denning M, Kopan R, Yuspa SH, The black box illuminated: signals and signaling. The Journal of investigative dermatology 132, 811 (3, 2012). 22170487 PMC6340394
  30. [30]Surguladze D, Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer research 69, 5643 (7 15, 2009). 19584274
  31. [31]Gerber PA, Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. Journal of the American Academy of Dermatology 63, 163 (7, 2010). 20542181
  32. [32]Gnant M, Clezardin P, Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer treatment reviews 38, 407 (8, 2012). 21983264
  33. [33]Kinugawa S, Tetracyclines convert the osteoclastic-differentiation pathway of progenitor cells to produce dendritic cell-like cells. J Immunol 188, 1772 (2 15, 2012). 22250082
  34. [34]Lacouture ME, Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 19, 1079 (8, 2011). 21630130 PMC3128700
  35. [35]Dube PE, Epidermal growth factor receptor inhibits colitis-associated cancer in mice. The Journal of clinical investigation 122, 2780 (8 1, 2012). 22772467 PMC3408743
  36. [36]Yan F, Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. The Journal of clinical investigation 121, 2242 (6, 2011). 21606592 PMC3104743
  37. [37]Bradley PP, Priebat DA, Christensen RD, Rothstein G, Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. The Journal of investigative dermatology 78, 206 (3, 1982). 6276474
  38. [38]Lichti U, Anders J, Yuspa SH, Isolation and short-term culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodeficient mice. Nature protocols 3, 799 (2008). 18451788 PMC6299324

Cited by

Sorted by citations

Authors
Mascia, F., Lam, G., Keith, C., Garber, C., Steinberg, S. M., Kohn, E., & Yuspa, S. H.
Affiliations
National Institutes of Health (US)
Corresponding author
Yuspa, Stuart H.
ORCID
Venue
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Published
2013-08-21
Volume
5
Issue
199
Pages
199ra110-199ra110
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
DOI
10.1126/scitranslmed.3005773
PMC
PMC6324537
OpenAlex
W2170248468
Cited by
105
References
0
Citations by year
2026: 4 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 11 · 2021: 8 · 2020: 11 · 2019: 8 · 2018: 10 · 2017: 4 · 2016: 9 · 2015: 12 · 2014: 8 · 2013: 3
FWCI
12.52
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (Z99 CA999999)
Topics
  • Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pharmacology › Drug-Induced Adverse Reactions
Keywords
gefitinib, anti-EGFR therapy, rash, pruritus, skin immune homeostasis, macrophages, chemokines, mast cells, eosinophils, mouse model, adverse drug reactions, skin inflammation
MeSH terms
Gefitinib, Animals, Antineoplastic Agents, Blood Cell Count, Disease Models, Animal, Exanthema, Female, Humans, Macrophages, Male, Mice, Inbred C57BL, Ovarian Neoplasms, Quinazolines, RNA, Messenger, Skin, Mice, Knockout, Genes, erbB-1, Inflammation Mediators, Chemokines, Mice, Translational Research, Biomedical, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review